OverviewSuggest Edit

Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
TypePublic
Founded1991
HQDublin, IE
Websiteamarincorp.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Feb 2020)965(+83%)
Job Openings35
Revenue (FY, 2019)$429.8 M(+88%)
Share Price (Sept 2020)$3.8 (+5%)
Cybersecurity ratingCMore

Key People/Management at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

CFO
Declan Doogan

Declan Doogan

Chief Medical Officer
Show more

Amarin Office Locations

Amarin has offices in Dublin and Bridgewater Township
Dublin, IE (HQ)
Block C, 77 Sir John Rogerson's Quay, Dublin Docklands
Dublin, IE
Pembroke House Pembroke Street Upper
Bridgewater Township, US
440 US-22
Show all (3)

Amarin Financials and Metrics

Amarin Revenue

Amarin's revenue was reported to be $429.76 m in FY, 2019
USD

Revenue (Q2, 2020)

135.3m

Gross profit (Q2, 2020)

106.5m

Gross profit margin (Q2, 2020), %

78.7%

Net income (Q2, 2020)

4.4m

EBIT (Q2, 2020)

4.2m

Market capitalization (25-Sept-2020)

1.5b

Closing stock price (25-Sept-2020)

3.8

Cash (30-Jun-2020)

214.0m

EV

1.3b
Amarin's current market capitalization is $1.5 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

26.4m54.2m81.8m130.1m181.1m229.2m429.8m

Revenue growth, %

106%51%59%39%27%

Cost of goods sold

11.9m20.5m27.9m34.4m45.0m54.5m96.0m

Gross profit

14.4m33.7m53.9m95.7m136.2m174.7m333.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

5.5m15.9m17.7m21.5m25.5m33.1m32.7m34.6m45.2m47.4m43.9m52.6m55.3m73.3m100.8m112.4m155.0m135.3m

Cost of goods sold

2.8m3.7m4.2m5.0m5.4m5.6m6.4m7.5m6.9m8.9m8.5m8.2m11.4m11.9m10.6m12.8m13.5m17.1m22.8m25.4m34.8m28.8m

Gross profit

2.7m10.3m11.3m14.0m18.6m24.3m24.3m26.4m33.8m35.4m33.3m39.8m41.8m56.1m78.0m87.0m120.2m106.5m

Gross profit Margin, %

48%65%64%65%73%73%74%76%75%75%76%76%76%77%77%77%78%79%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

116.6m260.2m191.5m119.5m107.0m98.3m73.6m249.2m644.6m

Accounts Receivable

3.6m7.8m13.8m20.0m45.3m66.5m116.4m

Prepaid Expenses

1.8m3.3m1.6m2.6m3.2m3.5m2.9m13.3m

Inventories

21.3m21.2m13.7m19.0m20.5m30.3m57.8m76.8m
USDQ2, 2011

Financial Leverage

-0.9 x
Show all financial metrics

Amarin Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Amarin Online and Social Media Presence

Embed Graph

Amarin News and Updates

Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today provided an update following the decision by the U.S. Court of Appeals for the Federal Circuit in the company’s ongoing patent litigation. The Court upheld the March ruling by the U…

Amarin Sinks to Five-Month Low After Losing Ruling on Heart Drug

Amarin Loses Appeals Court Ruling Over Vascepa Heart Drug

Thinking about buying stock in Advanced Micro Devices, Lonestar Resources, Amarin Corp, SmileDirectClub, or Vera Bradley?

NEW YORK, Sept. 2, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, LONE, AMRN, SDC, and VRA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Thinking about buying stock in Aimmune Therapeutics, FSD Pharma, Amarin Corp, Trevena Inc, or American Airlines?

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AIMT, HUGE, AMRN, TRVN, and AAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe

Amarin to Build Dedicated Organization to Retain Substantial Value of One of the Most Anticipated Cardiovascular Drug Products in Decades

Amarin stock tanks nearly 70% after losing a patent battle over its key heart drug (AMRN)

The United States District Court of Nevada on Monday ruled that Amarin's patent claims for Vascepa, a heart drug that uses fish oil to lower triglycerides, are invalid, potentially giving generic drugmakers the opportunity to knock off the treatment.  Shares of Amarin shed nearly 70% Tuesday on th…
Show more

Amarin Blogs

Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract].

Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract]. jennifer.segal… Tue, 09/08/2020 - 14:56 Effects of AMR101 on lipid and inflammator…

Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract P1679].

Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract P1679]. jennifer.segal… Tue, 09/08/2020 - 14:54 Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients f…

Triglycerides 150 mg/dL and above are associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a real-world analysis [abstract P739].

Triglycerides 150 mg/dL and above are associated with an increased risk of peripheral arterial revascularization in high-risk statin-treated patients: a real-world analysis [abstract P739]. jennifer.segal… Tue, 09/08/2020 - 14:52 Triglycerides 150 mg/dL and above are associated with an inc…

Prevalence of hypertriglyceridaemia in statin treated very high-risk patients who might benefit from treatment with icosapent ethyl for secondary prevention in clinical practice–results of DYSIS.

Prevalence of hypertriglyceridaemia in statin treated very high-risk patients who might benefit from treatment with icosapent ethyl for secondary prevention in clinical practice–results of DYSIS. jennifer.segal… Tue, 09/08/2020 - 14:46 Prevalence of hypertriglyceridaemia in statin treated…

Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Risk Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology Content Import Tue, 09/01/2020 - 16:30 Amarin Supports Latest Clinical Res…

Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2020, the Annual Meeting of the European Society of Cardiology

Amarin-Supported Research and Analyses from Academic Collaborators to Be Featured in Five Presentations, Including Late-Breaking Science Presentation of Final EVAPORATE Study Results DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today
Show more

Amarin Frequently Asked Questions

  • When was Amarin founded?

    Amarin was founded in 1991.

  • Who are Amarin key executives?

    Amarin's key executives are Colin Stewart, Joseph S. Zakrzewski and John Thero.

  • How many employees does Amarin have?

    Amarin has 965 employees.

  • What is Amarin revenue?

    Latest Amarin annual revenue is $429.8 m.

  • What is Amarin revenue per employee?

    Latest Amarin revenue per employee is $445.3 k.

  • Who are Amarin competitors?

    Competitors of Amarin include ObsEva, Avid Bioservices and Antidote.

  • Where is Amarin headquarters?

    Amarin headquarters is located at Block C, 77 Sir John Rogerson's Quay, Dublin Docklands, Dublin.

  • Where are Amarin offices?

    Amarin has offices in Dublin and Bridgewater Township.

  • How many offices does Amarin have?

    Amarin has 3 offices.